GlassScriptPhysician profile
Lawrence Ray Palmiter
NPI 1770095580
$1,741.72
in general payments reported to CMS, 2019-2025
22 companies · $427 in 2025
The $427 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $375 · 2023: $554 · 2024: $386 · 2025: $427.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,367.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,366.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $836.66 | 2022-2025 | |
| Lundbeck LLC | $137.10 | 2022-2024 | Vyepti |
| Globus Medical, INC. | $133.34 | 2024-2025 | Si-Lok, Xlif, Tlif |
| Lilly USA, LLC | $90.35 | 2022-2025 | Emgality, Reyvow, Zepbound |
| Biohaven Pharmaceutical Holding Company LTD. | $60.91 | 2022 | |
| Relievant Medsystems, INC. | $58.11 | 2023 | Intracept |
| Pfizer INC. | $45.67 | 2023 | |
| Vertex Pharmaceuticals Incorporated | $45.09 | 2025 | |
| Abbott Laboratories | $44.28 | 2024-2025 | Proclaim |
| Collegium Pharmaceutical, INC. | $42.15 | 2022-2024 | Xtampza |
| Spr Therapeutics, INC | $33.36 | 2023 | Sprint Pns System |
| Bioventus LLC | $28.50 | 2025 | Xcell |
| Tonix Medicines, INC. | $25.20 | 2025 | Tonmya |
| Merz Pharmaceuticals, LLC | $24.28 | 2024 | Xeomin |
| Azurity Pharmaceuticals, INC. | $21.99 | 2025 | Azmiro |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fidia Pharma USA INC. | $21.64 | 2025 | Hymovis, Triluron |
| Nevro Corp. | $17.42 | 2023 | Senza |
| Grt US Holding, INC. | $17.34 | 2022 | |
| Averitas Pharma INC. | $16.32 | 2023 | Qutenza |
| Almatica Pharma LLC | $16.16 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $12.93 | 2023 | Seglentis |
| Currax Pharmaceuticals LLC | $12.92 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Palmiter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.